期刊文献+

前列腺癌的基因治疗 被引量:1

Progress of the gene therapy for prostate cancer
下载PDF
导出
摘要 面对治疗前列腺癌有限的几种治疗模式,其有限的成功率势必需要一种更加有效的治疗方案作为替代或补充,随着生物科技的迅速发展,前列腺癌基因治疗的研究也在不断的深入,基于前列腺癌的分子表达,通过基因介导以达到治疗的目的,在研究过程当中多种基因治疗方案已经取得了很大的发展,这些方法主要有以下几类:免疫基因治疗;细胞减数基因治疗;条件复制型腺病毒。我们相信这些新的治疗方案在不久的将来定将给患者带来巨大的福音,现对这一方法进行综述。 In view of the limited success of available treatment modalities for prostate cancer,alternative and complementary strategies need to be developed.With the rapid development of bio-technology,prostate cancer gene therapy is also ongoing in-depth process.In delineation of the molecular basis of prostate cancer provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purpose.In this regard several gene therapy approaches for carcinoma of the prostate have been developed.These approaches can be divided into three categories:immune-based gene therapy;cytotoxic gene therapy;conditionally replicating oncolytic adenoviruses.Clinicians and scientists focused on the progress of such preclinical researches,we are sure that the therapeutic outcome would bring great gospel to the patients in future.
出处 《现代肿瘤医学》 CAS 2012年第1期186-190,共5页 Journal of Modern Oncology
基金 黑龙江省科技计划(编号:LC08C16) 黑龙江省教育厅海外学人科研资助项目(编号:1152hq26)
关键词 前列腺癌 基因治疗 腺病毒 prostate cancer gene therapy adenovirus
  • 相关文献

参考文献41

  • 1Terasawa H,Tsang KY,Gulley J,et al.Identification and characterization of a human agonist cytotoxic T lymphocyte epitope of human prostate -specific antigen[J].Clin Cancer Res,2002,8(1):41-45.
  • 2Huggins C,Hodges CV.Studies on prostatic cancer:The effect of castration,of estrogen and of androgen injection on the serum phosphatases in metastatic carcinoma of prostate[J].J Urol,2002,168(1):9-12.
  • 3Chen CD,Welsbie DS,Tran C,et al.Molecular determinants of resistance to antiandrogen therapy[J].Nat Med,2004,10(1):33-39.
  • 4Hegeman RB,Liu G,Wilding G,et al.Newer therapies in advanced prostate cancer[J].Clin Prostate Cancer,2004,3(3):150-156.
  • 5Madan RA,Aragon-Ching JB,Gulley JL,et al.From clinical trials to clinical practice:therapeutic cancer vaccines for the treatment of prostate cancer[J].Expert Rev Vaccines,2011,10(6):743-753.
  • 6Mabjeesh NJ,Zhong H,Simons JW.Gene therapy of prostate cancer:current and future directions[J].Endocr Relat Cancer,2002,9(2):115-139.
  • 7翟振兴,王志平.前列腺癌基因治疗的进展[J].现代泌尿生殖肿瘤杂志,2009,1(5):308-311. 被引量:2
  • 8Marxa L Figueiredo,Chinghai Kao,Lily Wu.Advance in preclinical investigation of prostate cancer gene therapy[J].Mol Ther,2007,15 (6):1053-1064.
  • 9Salgia R,Lynch T,Skarin A,et al.Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma[J].J Clin Oncol,2003,21(4):624-630.
  • 10Michae lA,Ball G,Quatan N,et al.Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables[J].Clin Cancer Res,2005,11(12):4469-4478.

二级参考文献75

  • 1张晓军,刘长庭,陶爱林,何韶衡.肺癌组织中bax、bcl-xL、bcl-xS基因表达的研究[J].现代肿瘤医学,2005,13(4):439-441. 被引量:2
  • 2刘宇,张幸平,邓红彬,陈鸿雁,徐曼,李园园,周道安.bcl-2、bax和p53在鼻咽鳞癌中的表达及其与瘤细胞凋亡的关系[J].现代肿瘤医学,2006,14(7):798-799. 被引量:6
  • 3Thompson IM,Pauler DK,Goodman PJ,et al.Prevalence of prostate cancer among men with a prostate-specific antigen level or 4.0 ng per milliliter[J].N Engl J Med,2004,350:2239.
  • 4Thompson IM,Ankerst DP,Chi C,et al.Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower[J].JAMA,2005,294:66.
  • 5Carter HB,Pearson JD,Metter EJ,et al.Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease[J].JAMA,1992,267:2215.
  • 6Benson MC,Whang IS,Olsson CA,et al.The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen[J].J Urol,1992,147:817.
  • 7Oesterling JE,Jacobsen SJ,Cooner WH.The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older[J].J Urol,1995,153:1160.
  • 8Schmid HP.Tumour markers in patients on deferred treatment:prostate specific antigen doubling times[J].Cancer Surv,1995,23:157.
  • 9Partin AW,Brawer MK,Bartsch G,et al.Complexed prostate specific antigen improves specificity for prostate cancer detection:results of a prospective multicenter clinical trial[J].J Urol,2003,170:1787.
  • 10Etzioni R,Falcon S,Gann PH,et al.Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer:do combination tests improve detection[J]? Cancer Epidemiol Biomarkers Prev,2004,13:1640.

共引文献6

同被引文献22

  • 1谢英,叶丽亚,张小滨,侯新朴,娄晋宁.血脑屏障体外实验模型的建立[J].北京大学学报(医学版),2004,36(4):435-438. 被引量:16
  • 2Demeule M, Regina A, Che C, et al. Identification and Design of peptides as a new drug delivery system for the brain [J]. J Pharmacol Exp Ther,2011,324 ( 3 ) : 1064-1072.
  • 3Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2 [J]. J Neurochem, 2011,106 (4) : 1534-1544.
  • 4Swami A, Goyai R,Tripathi SK, et al. Effect of homobifunctionai crosslinkers on nucleic acids delivery ability of PEL nanoparticles [J]. Int J Pharm,2011,374(1 -2) :125-138.
  • 5Shinde RR, Bachmann MH,Wang Q, et al. PEG-PLA/PLGA Nanopartictes for in-Vivo RNAi Delivery [ C ]. NSTI Nanotech. California, 2011 : 45-47.
  • 6Huang RQ, Qu YH, Ke WL, et al. Efcient gene delivery targeted to the brain using a transferrinconjugated polyethyleneglycol-modied polyamidoamine dendrimer [ J ]. FASEB J ,2010,21 (4) : 1117-1125.
  • 7Bielinska AU, Chen C, Johnson J, et al. DNA complexing with polyamidoamine dendrimers: implications for transfection [J]. Bioconjug Chem, 2011,10(5) : 843-850.
  • 8Choi JS, Nam K Park JY, et al. Enhanced transfection efficiency of PAMAM dendrimer by surface rnodifieation with Larginine [J]. J Control Release ,2011, 99 ( 3 ) :445-456.
  • 9Huang RQ, Ke WL, Liu Y, et al. The use of lactoferrin as a ligand for targetintg the polyanidoamine-based gene delivery system to the brain [J]. Biomaterials, 2011,29(2) :238-246.
  • 10Hussain MM, Strickland DK, Bakillah A. The mammalian low-density lipoprotein receptor family [ J ]. Annu Rev Nutr, 2011,19 : 141-172.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部